FLT3 and acute myeloid leukemia: Subgroup analysis showed a significant improvement in NPM1-mut AML patients treated with FLAG-Ida-GO compared to DA-GO (Os 82% vs. 64% respectively at 3 years); concerning FLT3-ITD-mutated patients, a significant OS benefit was observed among NPM1-mut/FLT3-mut patients [107].